Melatonin: An inhibitor of breast cancer

Endocrine-Related Cancer

Volumn 22, Issue 3, 2015, Pages R183-R204

  Hill, Steven M ^a   Belancio, Victoria P ^a   Dauchy, Robert T ^a   Xiang, Shulin ^a   Brimer, Samantha ^a   Mao, Lulu ^a   Hauch, Adam ^a   Lundberg, Peter W ^a   Summers, Whitney ^a   Yuan, Lin ^a   Frasch, Tripp ^a   Blask, David E ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Circadian disruption; Drug resistance; Genomic instability; Melatonin; Molecular signaling; Nuclear receptors

Indexed keywords

ANTIMETASTATIC AGENT; CELL NUCLEUS RECEPTOR; CRYPTOCHROME 1; CYTOSTATIC AGENT; DOXORUBICIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSCRIPTION FACTOR CLOCK;

AEROBIC METABOLISM; APOPTOSIS; BREAST CANCER; BREAST CANCER CELL LINE; BREAST METASTASIS; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CIRCADIAN RHYTHM; CYTOTOXICITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENOMIC INSTABILITY; HORMONAL THERAPY; HORMONE ACTION; HUMAN; LIGHT; NIGHT; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; RETROPOSON; REVIEW; TRANSACTIVATION; TUMOR XENOGRAFT; ANIMAL; FEMALE; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; CIRCADIAN RHYTHM; FEMALE; HUMANS; MELATONIN; SIGNAL TRANSDUCTION;

EID: 84937032726     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-15-0030     Document Type: Review

References (178)

1. Acuña-Castroviejo D, Escames G, Venegas C, Díaz-Casado ME, Lima-Cabello E, López LC, Rosales-Corral S, Tan DX & Reiter RJ 2014 Extrapineal melatonin: sources, regluation, and potential functions. Cellular and Molecular Life Sciences 71 2997-3025. (doi:10.1007/s00018-014-1579-2)
2. Adb El-Aziz MA, Hassan HA, Mohamed MH, Meki AR, Abdel-Ghaffar SK & Hussein MR 2005 The biochemical and morphological alterations following administration ofmelatonin, retinoic acid and Nigell satvia in mammary carcinoma: an animal model. International Journal of Experimental Pathology 86 383-396. (doi:10.1111/j.0959-9673.2005.00448.x)
3. Anbalagan M, Carrier L, Glodowski S, Hangauer D, Shan B & Rowan BG 2012 KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor a positive breast cancer. Breast Cancer Research and Treatment 132 391-409. (doi:10.1007/s10549-011-1513-3)
4. Austreid E, Lonning PE & Eikesdal HP 2014 The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. Expert Opinion on Pharmacotherapy 5 681-700. (doi:10.1517/14656566.2014.885952)
5. AyoubMA, Couturier C, Lucas-Meunier E, Angers S, Fossier P, BouvierM & Jockers R 2002 Monitoring of ligand-independent dimerization and ligand-induced conformational changes ofmelatonin receptors in living cells by bioluminescence resonance energy transfer. Journal Biological Chemistry 277 21522-21528. (doi:10.1074/jbc.M200729200)
6. Bao AM, Liu RY, van Someren EJ, Hofman MA, Cao YX & Zhou JN 2003 Diurnal rhythm of free estradiol during the menstrual cycle. European Journal of Endocrinology 148 227-232. (doi:10.1530/eje.0.1480227)
7. Barrett P & BolboreaM2012 Molecular pathways involved in seasonal body weight and reproductive responses governed by melatonin. Journal of Pineal Research 52 376-388. (doi:10.1111/j.1600-079X.2011.00963.x)
8. Becker-André M, Wiesenberg I, Schaeren-Wiemers N, André E, MissbachM, Saurat JH & Carlberg C 1994 Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. Journal of Biological Chemistry 269 28531-28534.
9. Belancio VP, Roy-Engel AM & Deininger PL 2010 All y'all need to know 0bout retroelements in cancer. Seminars in Cancer Biology 20 200-210. (doi:10.1016/j.semcancer.2010.06.001)
10. Belancio VP, Blask DE, Deininger P, Hill SM & Jazwinski SM 2015 The aging clock and circadian control of metabolism and genome stability. Frontiers in Genetics 5 455-463. (doi:10.3389/fgene.2014.00455)
11. Benítez-King G, Huerto-Delgadillo L & Antón-Tay F 1990 Melatonin effects on the cytoskeletal organization of MDCK and neuroblastoma N1E-115 cells. Journal of Pineal Research 9 209-220.
12. ten Berge D, Koole W, Fuerer C, Fish M, Eroglu E & Nusse R 2008 Wnt signaling mediates self-organization and axis formation in embryoid bodies. Cell Stem Cell 3 508-518. (doi:10.1016/j.stem.2008.09.013)
13. Berson DM, Dunn FA & Takao M 2002 Phototransduction by retinal ganglion cells that set the circadian clock. Science 295 1070-1073. (doi:10.1126/science.1067262)
14. Blask DE 2009 Melatonin, sleep disturbance and cancer risk. Sleep Medicine Reviews 13 252-264. (doi:10.1016/j.smrv.2008.07.007)
15. Blask DE, Pelletier DB, Hill SM, Lemus-Wilson A, Grosso DS, Wilson ST & Wise ME 1991 Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: potential involvement of antiestrogenic mechanisms in vivo. Journal of Cancer Research and Clinical Oncology 117 526-532. (doi:10.1007/BF01613283)
16. Blask DE, Wilson ST & Zalatan F 1997 Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathionemediated pathway. Cancer Research 57 1909-1914.
17. Blask DE, Sauer LA, Dauchy RT, Armstrong BJ & Scalici S 1999 Melatonin inhibition of cancer growth in vivo involves suppression of tumor FA metabolism via melatonin receptor-mediated signal transduction events. Cancer Research 59 4693-4701.
18. Blask DE, Brainard GC, Dauchy RT, Hanifin JP, Davidson LK, Krause JA, Sauer LA, Rivera-Bermudez MA, Dubocovich ML, Jasser SA et al. 2005 Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Research 65 11174-11184. (doi:10.1158/0008-5472. CAN-05-1945)
19. Blask DE, Hill SM, Dauchy RT, Xiang S, Yuan L, Duplessis T, Mao L, Dauchy E & Sauer LA 2011 Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night. Journal of Pineal Research 51 259-269. (doi:10.1111/j.1600-079X.2011.00888.x)
20. Blask DE, Dauchy RT, Dauchy EM, Mao L, Hill SM, GreeneMW, Belancio VP, Sauer LA & Davidson L 2014 Light exposure at night disrupts host/cancer circadian regulatory dynamics: impact on the Warburg effect, lipid signaling and tumor growth prevention. PLoS ONE 9 e102776. (doi:10.1371/journal.pone.0102776)
21. Bondi CD, Alonso-Gonzalez C, Clafshenkel WP, Kotlarczyk MP, Dodda BR, Sanchez-Barcelo E, Davis VL & Witt-Enderby PA 2014 The effect of estradiol, progesterone, and melatonin on estrous cycling and ovarian aromatase expression in intact female mice. European Journal of Obstetrics, Gynecology, and Reproductive Biology 174 80-85. (doi:10.1016/j.ejogrb.2013.11.027)
22. Bracke ME, Larebeke NA, Vyncke BM & Mareel MM 1991 Retinoic acid modulates both invasion and membrane ruffling in MCF-7 human mammary carcinoma cells in vitro. British Journal of Cancer 63 867-872. (doi:10.1038/bjc.1991.191)
23. Brainard GC, Hanifin JP, Greeson JM, Byrne B, Glickman G, Gerner E & Rollag MD 2001 Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor. Journal of Neuroscience 21 6405-6412.
24. Brouha B, Badge R, Schustak J, Lutz-Prigge S, Farley AH, Moran JV & Kazazian HH Jr 2002 Active L1 retrotransposons in the human genome. American Journal of Human Genetics 71 410. (doi:10.1086/341722)
25. Brouha B, Schustak J, Badge RM, Lutz-Prigge S, Farley AH, Moran JV & Kazazian HH Jr 2003 Hot L1s account for the bulk of retrotransposition in the human population. PNAS 100 5280-5285. (doi:10.1073/pnas. 0831042100)
26. Brydon L, Roka F, Petit L, de Coppet P, Tissot M, Barrett P, Morgan PJ, Nanoff C, Strosberg AD & Jockers R 1999 Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3), and G(q/11) proteins. Molecular Endocinology 13 2025-2038. (doi:10.1210/mend.13.12.0390)
27. Burris HA 2013 Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemotherapy and Pharmacology 4 829-842. (doi:10.1007/s00280-012-2043-3)
28. Carrillo-Vico A, García-Mauriño S, Calvo JR & Guerrero JM 2003 Melatonin counteracts the inhibitory effect of PGE2 on IL-2 production in human lymphocytes via its mt1 membrane receptor. FASEB Journal 17 755-765.
29. Chen A, Beetham H, Black MA, Priya R, Telford BJ, Guest J, Wiggins GA, Godwin TD, Yap AS & Guilford PJ 2014 E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition. BMC Cancer 14 552-559. (doi:10.1186/1471-2407-14-552)
30. Claustrat B, Brun H & Chazot G 2005 The basic physiology and pathophysiology of melatonin. Sleep Medicine Reviews 9 11-24. (doi:10.1016/j.smrv.2004.08.001)
31. Collins A, Yuan Y, Kiefer TL, Cheng Q, Lai L & Hill SM 2003 Over-expression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice. Cancer Letters 189 49-57. (doi:10.1016/S0304-3835(02)00502-5)
32. Cos S & Sanchez-Barcelo EJ 2000 Melatonin and mammary pathological growth. Frontiers in Neuroendocrinology 21 133-170. (doi:10.1006/frne.1999.0194)
33. Cos S, Blask DE, Lemus-Wilson A & Hill AB 1991 Effects of melatonin on the cell cycle kinetics and 'estrogen-rescue' of MCF-7 human breast cancer cells in culture. Journal of Pineal Research 10 36-42. (doi:10.1111/j.1600-079X.1991.tb00007.x)
34. Cos S, Fernandez R, Guezmes A & Sánchez-Barceló EJ 1998 Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Research 58 4383-4390.
35. Cucina A, Proietti S, D'Anselmi F, Coluccia P, Dinicola S, Frati L & BizzarriM 2009 Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. Journal of Pineal Research 46 172-180. (doi:10.1111/j.1600-079X.2008.00645.x)
36. Dai J, Ram PT, Yuan L, Spriggs L & Hill SM 2001 Transcriptional repression of RORa activity in human breast cancer cells by melatonin. Molecular and Cellular Endocrinology 176 111-120. (doi:10.1016/S0303-7207(01)00449-X)
37. Dai J, Inscho EW, Yuan L & Hill SM 2002 Modulation of intracellular calcium and calmodulin by melatonin in MCF-7 human breast cancer cells. Journal of Pineal Research 32 112-119. (doi:10.1034/j.1600-079x. 2002.1844.x)
38. Dai H, Zhang L, Cao M, Song F, Zheng H, Zhu X, Wei Q, ZhangW& Chen K 2011 The role of polymorphisms in circadian pathway genes in breast tumorigenesis. Breast Cancer Research and Treatment 127 531-540. (doi:10.1007/s10549-010-1231-2)
39. Dauchy RT, Dauchy EM, Sauer LA, Blask DE, Davidson LK, Krause JA & Lynch DT 2004 Differential inhibition of fatty acid transport in tissue-isolated steroid receptor negative human breast cancer xenografts perfused in situ with isomers of conjugated linoleic acid. Cancer Letters 209 7-15. (doi:10.1016/j.canlet.2003.12.012)
40. Dauchy RT, Xiang S, Mao L, Brimer S, Wren MA, Yuan L, Anbalagan M, Hauch A, Frasch T, Rowan BG et al. 2014 Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. Cancer Research 74 4099-4110. (doi:10.1158/0008-5472.CAN-13-3156)
41. Davis S, Mirick DK & Stevens RG 2001 Night shift work, light at night, and risk of breast cancer. Journal of the National Cancer Institute 93 1557-1562. (doi:10.1093/jnci/93.20.1557)
42. DeBerardinis RJ, Lum JJ, Hatzivassiliou G & Thompson CB 2008 The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metabolism 7 11-20. (doi:10.1016/j.cmet.2007.10.002)
43. Deharo D, Kines KJ, Sokolowski M, Dauchy RT, Streva VA, Hill SM, Hanifin JP, Brainard GC, Blask DE & Belancio VP 2014 Regulation of L1 expression and retrotransposition by melatonin and its receptor: implications for cancer risk associated with light exposure at night. Nucleic Acids Research 42 7694-7707. (doi:10.1093/nar/gku503)
44. Del Rio B, Garcia Pedrero JM, Martinez-Campa C, Zuazua P, Lazo PS & Ramos S 2004 Melatonin, an endogenous-specific inhibitor of estrogen receptor a via calmodulin. Journal Biological Chemistry 279 38294-38302. (doi:10.1074/jbc.M403140200)
45. Díaz-Bessone MI, Berardi DE, Campodónico PB, Todaro LB, Lothstein L, Bal de Kier Joffé ED & Urtreger AJ 2011 Involvement of PKC δ (PKCδ) in the resistance against different doxorubicin analogs. Breast Cancer Research and Treatment 126 577-587. (doi:10.1007/s10549-010-0956-2)
46. Dinet V & Korf HW 2007 Impact of melatonin receptors on pCREB and clock-gene protein levels in the murine retina. Cell and Tissue Research 330 29-34. (doi:10.1007/s00441-007-0468-5)
47. Dong C, Yuan L, Dai J, Lai L, Mao L, Xiang S, Rowan B & Hill SM 2010 Melatonin inhibits mitogenic cross-talk between retinoic acid-related orphan receptor a (RORa) and ERα in MCF-7 human breast cancer cells. Steroids 75 944-951. (doi:10.1016/j.steroids.2010.06.002)
48. Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ & Masana MI 2003 Molecular pharmacology, regulation and function of mammalian melatonin receptors. Frontiers in Bioscience 8 d1093-d1108. (doi:10.2741/1089)
49. Dubocovich ML, Delarange P, Krause DN, Sugden D, Cardinali DP & Olcese J 2010 International union of basic and clinical pharmacology. LXXV Nomenclature, classification, and pharmacology of G-protein-coupled melatonin receptors. Pharmacological Reviews 62 343-380. (doi:10.1124/pr.110.002832)
50. Eck KM, Yuan L, Duffy L, Ram PT, Ayettey S, Chen I, Cohn CS, Reed JC & Hill SM 1998 A sequential treatment regimen with melatonin and all-trans retinoic acid induces apoptosis in MCF-7 tumor cells. British Journal of Cancer 77 2129-2137. (doi:10.1038/bjc.1998.357)
51. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM et al. 2004 Akt stimulates aerobic glycolysis in cancer cells. Cancer Research 64 3892-3899. (doi:10.1158/0008-5472.CAN-03-2904) Erratum in: 1997, Journal of Biological Chemistry 272 16707.
52. Evrony GD, Cai X, Lee E, Hills LB, Elhosary PC, Lehmann HS, Parker JJ, Atabay KD, Gilmore EC, Poduri A et al. 2012 Single-neuron sequencing analysis of l1 retrotransposition and somatic mutation in the human brain. Cell 151 483-496. (doi:10.1016/j.cell.2012.09.035)
53. Fan LL, Sun GP, WeiW, Wang ZG, Ge L, Fu WZ & Wang H 2010 Melatonin and doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines. World Journal of Gastroenterology 16 1473-1481. (doi:10.3748/wjg.v16.i12.1473)
54. Fantin VR, St-Pierre L & Leder P 2006 Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9 425-434. (doi:10.1016/j. ccr.2006.04.023)
55. García JJ, Reiter RJ, Ortiz GG, Oh CS, Tang L, Yu BP & Escames G 1988 Melatonin enhances tamoxifen's ability to prevent the reduction in microsomal membrane fluidity induced by lipid peroxidation. Journal of Membrane Biology 162 59-65.
56. Gariboldi MB, Ravizza R, Riganti L, Meschini S, Calcabrini A, Marra M, Arancia G, Dolfini E & Monti E 2003 Molecular determinants of intrinsic resistance to doxorubicin in human cancer cell lines. International Journal of Oncology 22 1057-1064.
57. Gery S & Koeffler HP 2009 Per2 is a C/EBP target gene implicated in myeloid leukemia. Integrative Cancer Therapies 8 317-320. (doi:10.1177/1534735409352084)
58. Gery S, Virk RK, Chumakov K, Yu A & Koeffler HP 2007 The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene 26 7916-7920. (doi:10.1038/sj.onc.1210585)
59. Gilles C, Poliette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P & Foidart JM 2003 Transactivation of vimentin by β-catenin in human breast cancer cells. Cancer Research 63 2658-2664.
60. Glasgow WC & Eling TE 1994 Structure-activity relationship for potentiation of EGF-dependentmitogenesis by oxygenated metabolites of linoleic acid. Archives of Biochemistry and Biophysics 311 286-292. (doi:10.1006/abbi.1994.1239)
61. Glasgow WC, Hui R, Everhart AL, Jayawickreme SP, Angerman-Stewart J, Han BB & Eling TE 1997 The linoleic acid metabolite, (13S)-hydroperoxyoctadecadienoic acid, augments the epidermal growth factor receptor signaling pathway by attenuation of receptor dephosphorylation. Differential response in Syrian hamster embryo tumor suppressor phenotypes. Journal Biological Chemistry 272 19269-19276. (doi:10.1074/jbc.272.31.19269)
62. González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Mateos S, Hill SM, Sánchez-Barceló EJ & Cos S 2007 Effects of MT1 melatonin receptor overexpression on the aromatase-suppressive effect of melatonin in MCF-7 human breast cancer cells. Oncology Reports 17 947-953.
63. Gonzalez-Angulo AM, Morales-Vasquez F & Hortobagyi GN 2007 Overview of resistance to systemic therapy in patients with breast cancer. Advances in Experimental Medicine and Biology 608 1-22.
64. Gordge PC, Hulme MJ, Clegg RA & Miller WR 1996 Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue. European Journal of Cancer 32A 2120-2126. (doi:10.1016/S0959-8049(96)00255-9)
65. Gordan JD, Thompson CB & Simon MC 2007 HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 12 108-113. (doi:10.1016/j.ccr.2007.07.006)
66. Gottesman MM, Fojo T & Bates SE 2002 Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews. Cancer 2 48-58. (doi:10.1038/nrc706)
67. deGraffenried LA, Chandrasekar B, Friedrichs WE, Donzis E, Silva J, Hidalgo M, Freeman JW & Weiss GR 2004 NF-κ B inhibition markedly enhances sensitivity of resistant breast tumor cells to tamoxifen. Annals of Oncology 15 885-890. (doi:10.1093/annonc/mdh232)
68. Grant SG, Melan MA, Latimer JJ & Witt-Enderby PA 2009 Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives. Expert Reviews in Molecular Medicine 11 1-15. (doi:10.1017/S1462399409000982)
69. Hastings M, Reddy AB & Maywood ES 2003 A clockwork web: circadian timing in brain and periphery, in health and disease. Nature Reviews. Neuroscience 4 649-661. (doi:10.1038/nrn1177)
70. Hill SM & Blask DE 1988 Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Research 48 6121-6126.
71. Hill SM, Spriggs LL, Simon MA, Muraoka H & Blask DE 1992 The growth inhibitory action ofmelatonin on human breast cancer cells is linked to the estrogen response system. Cancer Letters 64 249-256. (doi:10.1016/0304-3835(92)90050-6)
72. Hill SM, Blask DE, Xiang S, Yuan L, Mao L, Dauchy RT, Dauchy EM, Frasch T & Duplesis T 2011 Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer. Journal of Mammary Gland Biology and Neoplasia 16 235-245. (doi:10.1007/s10911-011-9222-4)
73. Hollestelle A, Peeters JK, SmidM, TimmermansM, Verhoog LC, Westenend PJ, Heine AA, Chan A, Sieuwerts AM, Wiemer EA et al. 2013 Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer. Breast Cancer Research and Treatment 138 47-57. (doi:10.1007/s10549-013-2415-3)
74. Hsi LC, Wilson LC & Eling TE 2002 Opposing effects of 15-lipoxygenase-1 and-2 metabolites on MAPK signaling in prostate. Alteration in peroxisome proliferator-activated receptor γ. Journal of Biological Chemistry 277 40549-40556. (doi:10.1074/jbc.M203522200)
75. Hua G, Liu Y, Li X, Xu P & Luo Y 2014 Targeting glucose metabolism in chondrosarcoma cells enhances the sensitivity to doxorubicin through the inhibition of lactate dehydrogenase-A. Oncology Reports 31 2727-2734. (doi:10.3892/or.2014.3156)
76. Huether G 1993 The contribution of extrapineal sites of melatonin synthesis to circulating melatonin levels in higher vertebrates. Experientia 49 665-670. (doi:10.1007/BF01923948)
77. Ingber DE 2003 Tensegrity II. How structural networks influence cellular information processing networks. Journal of Cell Science 116 1379-1408.
78. Jablonska K, Pula B, Zemia A, Owczarek T, Wojnar A, Rys J, Ambicka A, Podhorska-Okolow M, Ugorski M & Dziegiel P 2013 Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinoma. Journal of Pineal Research 54 334-345. (doi:10.1111/jpi.12032)
79. Jasser SA, Blask DE & Brainard GC 2006 Light during darkness and cancer: relationships in circadian photoreception and tumor biology. Cancer Causes & Control 17 515-523. (doi:10.1007/s10552-005-9013-6)
80. Jechlinger M, Grunert S, Tamir IH, Janda E, Lundemann S, Waerner T, Seither P, Weith A, Beug H & Kraut N 2003 Expression profiling of epithelial plasticity in tumor progression. Oncogene 22 7155-7169. (doi:10.1038/sj.onc.1206887)
81. Kalay E, Yigit G, Aslan Y, Brown KE, Pohl E, Bicknell LS, Kayserili H, Li Y, Tüysüz B, Nürnberg G et al. 2011 CEP152 is a genomic maintenance protein disrupted in Seckel syndrome. Nature Genetics 43 23-26. (doi:10.1038/ng.725)
82. Kassner N, Huse K, Martin HJ, Gödtel-Armbrust U, Metzger A, Meineke I, Brockmöller J, Klein K, ZangerUM, Maser E et al. 2008 Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug MetabolismandDisposition362113-2120. (doi:10.1124/dmd.108.022251)
83. Kelleher FC, Rao A & Maguire A 2014 Circadian molecular clocks and cancer. Cancer Letters 342 9-18. (doi:10.1016/j.canlet.2013.09.040)
84. Kiefer T, Yuan L, Ram P & Hill SM 2002 Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Research and Treatment 71 37-45. (doi:10.1023/A:1013301408464)
85. Kiefer TL, Lai L, Yuan L, Dong C, Burrow ME & Hill SM 2005 Differential regulation of estrogen receptor a, glucocorticoid receptor and retinoic acid receptor a transcriptional activity by melatonin is mediated via different G proteins. Journal of Pineal Research 38 231-239. (doi:10.1111/j.1600-079X.2004.00198.x)
86. Kohsaka A & Bass J 2007 A sense of time: how molecular clocks organize metabolism. Trends in Endocrinology and Metabolism 18 4-11. (doi:10.1016/j.tem.2006.11.005)
87. Lai L, Yuan L, Chen Q, Dong C, Mao L, Rowan B, Frasch T & Hill SM 2008 The Ga i and Ga q proteins mediate the effects of melatonin on steroid/thyroid hormone receptor transcriptional activity and breast cancer cell proliferation. Journal of Pineal Research 45 476-488. (doi:10.1111/j.1600-079X.2008.00620.x)
88. Lai L, Yuan L, Cheng Q, Dong C, Mao L & Hill SM 2009 Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines. Breast Cancer Research and Treatment 118 293-305. (doi:10.1007/s10549-008-0220-1)
89. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHughWet al. 2001 Initial sequencing and analysis of the human genome. Nature 409 860-921. (doi:10.1038/35057062)
90. Lapin V & Ebels I 1976 Effects of some low molecular weight sheep pineal fractions and melatonin on different tumors in rats and mice. Oncology 33 110-113. (doi:10.1159/000225117)
91. Lazennec G, Thomas JA & Katzenellenbogen BS 2001 Involvement of the CREB and estrogen receptor phosphorylation in the synergistic action of the estrogen receptor by estradiol and protein kinase activators. Journal of Steroid Biochemistry and Molecular Biology 77 193-203. (doi:10.1016/S0960-0760(01)00060-7)
92. Lee SA, Karaszkiewicz JW & Anderson WB 1992 Elevated level of nuclear protein kinase C in multidrug-resistant MCF-7 human breast carcinoma cells. Cancer Research 52 3750-3759.
93. Lee SE, Kim SJ, Yoon JP, Hwang SY, Park CS & Park YS 2011 MircroRNA and gene expression analysis of melatonin-exposed human breast cancer cell lines indicating involvement of the anticancer effect. Journal of Pineal Research 51 345-352. (doi:10.1111/j.1600-079X.2011.00896.x)
94. Lee SE, Kim SJ, Yoon HJ, Yu SY, Yang H, Jeong SI, Hwang SY, Park CS & Park YS 2013 Genome-wide profiling in melatonin-exposed human breast cancer cell lines identifies differentially methylated genes involved in the anticancer effect of melatonin. Journal of Pineal Research 54 80-88. (doi:10.1111/j.1600-079X.2012.01027.x)
95. Leon-Blanco MM, Guerrero JM, Reiter RJ, Calvo JR & Pozo D 2003 Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. Journal of Pineal Research 35 204-211. (doi:10.1034/j.1600-079X.2003.00077.x)
96. Lerner AB, Case JD & Takahashi Y 1960 Isolation of melatonin and 5-methoxyindole-3-acetic acid from bovine pineal glands. Journal Biological Chemistry 235 1992-1997.
97. Levoye A, Dam J, Ayoub MA, Guillaume JL, Couturier C, Delagrange P & Jockers R 2006 The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO Journal 25 3012-3023. (doi:10.1038/sj.emboj.7601193)
98. Lewis-Wambi JS & Jordan VC 2006 Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs). Breast Disease 24 93-105.
99. Li Q, Mullins SR, Sloane BF & Mattingly PR 2008 P21-activated kinase 1 coordinates aberrant cell survival and pericellular proteolyisis in a three-demensional culture model for premalignant progression of human breast cancer. Neoplasia 10 314-328. (doi:10.1593/neo.07970)
100. Lissoni P, Tisi E, Brivio F, Crispino S, Barni S, Tancini G, Conti A & Maestroni GJ 1991 Modulation of interleukin-2-induced macrophage activation by the pineal hormone melatonin in cancer patients. Journal of Biological Regulators and Homeostatic Agents 5 154-156.
101. Lissoni P, Barni S, Meregalli S, Fossati V, Cazzaniga M, Esposti D & Tancini G 1995 Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. British Journal of Cancer 71 854-856. (doi:10.1038/bjc.1995.164)
102. Lissoni P, Barni S, Mandala M, Ardizzoia A, Paolorossi F, Vaghi M, Longarini R, Malugani F & Tancini G 1999 Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin inmetastatic solid tumour patients with poor clinical status. European Journal of Cancer 35 1688-1692. (doi:10.1016/S0959-8049 (99)00159-8)
103. Liu R, Fu A, Hoffman AE & Zhu Y 2013 Melatonin enhances DNA repair capacity possibly by affecting genes involved in DNA damage responsive pathways. BMC Cell Biology 14 1-6. (doi:10.1186/1471-2121-14-1)
104. Locasale JW & Cantley LC 2010 Altered metabolism in cancer. BMC Biology 8 88. (doi:10.1186/1741-7007-8-88)
105. Mao L, Yuan L, Slakey LM, Jones FE, Burow ME & Hill SM 2010 Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of p38 mitogen-activated protien kinase signaling pathway. Breast Cancer Research 12 R107. (doi:10.1186/bcr2794)
106. Mao L, Dauchy RT, Blask DE, Slakey LM, Xiang S, Yuan L, Dauchy EM, Shan B, Brainard GC, Hanifin JP et al. 2012 Circadian gating of epithelial-to-mesenchymal transition in breast cancer cells via melatonin regulation of GSK3b. Molecular Endocinology 26 1808-1820. (doi:10.1210/me.2012-1071)
107. Mao L, Yuan L, Xiang S, Zeringue SB, Dauchy RT, Blask DE, Hauch A & Hill SM 2014 Molecular deficiency(ies) in MT1 melatonin signaling pathway underlies the melatonin-unresponsive phenotype in MDAMB-231 human breast cancer cells. Journal of Pineal Research 56 246-253. (doi:10.1111/jpi.12117)
108. Martínez-Campa C, González A, Mediavilla MD, Alonso-González C, Alvarez-García V, Sánchez-Barceló EJ & Cos S 2009 Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. British Journal of Cancer 101 1613-1619. (doi:10.1038/sj.bjc.6605336)
109. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A et al. 2007 Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et Biophysica Acta 1773 1263-1284. (doi:10.1016/j.bbamcr.2006.10.001)
110. Mediavilla MD, Cos S & Sanchez-Barcelo EJ 1999 Melatonin increases p53 and p21waf1 expression in MCF-7 human breast cancer cells in vitro. Life Sciences 65 415-420. (doi:10.1016/S0024-3205(99)00262-3)
111. Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, Manchester L & Reiter RJ 2010 Basic mechanisms involved in the anti-cancer effects of melatonin. Current Medicinal Chemistry 17 4462-4481. (doi:10.2174/092986710794183015)
112. Melancon K, Cheng Q, Kiefer TL, Dai J, Lai L, Dong C, Yuan L, Collins A, Thiyagarajah A, Long S et al. 2005 Regression ofNMU-inducedmammary tumors with the combination ofmelatonin and 9-cis-retinoic acid. Cancer Letters 227 39-48. (doi:10.1016/j.canlet.2005.01.005)
113. Molis TM, Spriggs LL & Hill SM 1994 Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Molecular Endocrinology 8 1681-1690.
114. Moriya T, Hiraishi K, Horie N, Mitome M & Shinohara K 2007 Correlative association between circadian expression of mousePer2 gene and the proliferation of the neural stem cells. Neuroscience 146 494-498. (doi:10.1016/j.neuroscience.2007.02.018)
115. Novotna R, Wsol V, Xiong G & Maser E 2008 Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR)1C3. Toxicology Letters 181 1-6. (doi:10.1016/j.toxlet.2008.06.858)
116. Oprea-Ilies G, Haus E, Sackett-Lundeen L, Liu Y, McLendon L, Busch R, Adams A & Cohen C 2013 Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival. Breast Cancer Research and Treatment 137 677-687. (doi:10.1007/s10549-012-2371-3)
117. Ortíz-López L, Morales-Mulia S, Ramírez-Rodríguez G & Benítez-King G 2009 ROCK-regulated cytoskeletal dynamics participate in the inhibitory effect of melatonin on cancer cell migration. Journal of Pineal Research 46 15-21. (doi:10.1111/j.1600-079X.2008.00600.x)
118. Pawlikowski M, Winczyk K & Karasek M 2002 Oncostatic action of melatonin: facts and question marks. Neuroendocrinology Letters 23 24-29.
119. Poeggeler B, Reiter RJ, Tan DX, Chen LD & Manchester LC 1993 Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis. Journal of Pineal Research 14 151-168. (doi:10.1111/j.1600-079X.1993.tb00498.x)
120. Proietti S, Cucina A, D'Anselmi F, Dinicola S, Pasqualato A, Lisi E & Bizzarri M 2011 Melatonin and vitamin D3 synergistically downregulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells. Journal of Pineal Research 50 150-158. (doi:10.1111/j.1600-079X.2010.00824.x)
121. Proietti S, Cucina A, Reiter R & Bizzarri M 2013 Molecular mechanisms of melatonin's inhibitory actions on breast cancer. Cellular and Molecular Life Sciences 70 2139-2157. (doi:10.1007/s00018-012-1161-8)
122. Proietti S, Cucina A, Dobrowoly G, D'Anselmi F, Dinicola S, Masiello MG, Pasqualato A, Palombo A, Morini V, Reiter RJ et al. 2014 Melatonin down-regulates MDM2 gene expression and enhances p53 acetylation in MCF-7 cells. Journal of Pineal Research 57 120-129. (doi:10.1111/jpi.12150)
123. Ram PT, Dai J, Yuan L, Dong C, Kiefer TL, Lai L & Hill SM 2002 Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Letters 179 141-150. (doi:10.1016/S0304-3835(01)00873-4)
124. Ramirez-Rodriguez G, Ortiz-Lopez L & Benitez-King G 2007 Melatonin increases stress fibers and focal adhesions in MDCK cells: participation of Rho-associated kinase and protein kinase C. Journal of Pineal Research 42 180-190. (doi:10.1111/j.1600-079X.2006.00404.x)
125. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ et al. 1992 Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. Journal of Clinical Oncology 8 1284-1291.
126. Reiter RJ 1980 The pineal and its hormones in the control of reproduction in mammals. Endocrine Review 1 109-131. (doi:10.1210/edrv-1-2-109)
127. Reiter RJ 1991 Melatonin: the chemical expression of darkness. Molecular and Cellular Endocrinology 79 C153-C158. (doi:10.1016/0303-7207(91)90087-9)
128. Reiter RJ, Tan DX, Korkmaz A, Erren TC, Piekarski C, Tamura H & Manchester LC 2007 Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. Critical Reviews in Oncogenesis 13 303-328. (doi:10.1615/CritRevOncog.v13.i4.30)
129. Revell VL & Skene DJ 2007 Light-induced melatonin suppression in humans with polychromatic and monochromatic light. Chronobiology International 24 1125-1137. (doi:10.1080/07420520 701800652)
130. Roberts K 1974 Cytoplasmic microtubules and their functions. Progress in Biophysics and Molecular Biology 28 371-420. (doi:10.1016/0079-6107(74)90022-4)
131. Robey RB & Nay JR 2009 Is Akt the 'Warburg kinase'?-Akt-energy metabolism interactions and oncogenesis Seminars in Cancer Biology 19 25-31. (doi:10.1016/j.semcancer.2008.11.010)
132. Rögelsperger O, Ekmekcioglu C, Jäger W, Klimpfinger M, Königsberg R, Krenbek D, Sellner F & Thalhammer T 2009 Coexpression of the melatonin receptor 1 and nestin in human breast cancer specimens. Journal of Pineal Research 46 422-432. (doi:10.1111/j.1600-079X.2009. 00679.x)
133. Romeo Y, Zhang X & Roux PP 2012 Regulation and function of the RSK family of protein kinases. Biochemical Journal 441 553-569. (doi:10.1042/BJ20110289)
134. Roskoski R 2014 The ERBB/HER family of protein-tyrosine kinases and cancer. Pharmacology Research 79 34-74. (doi:10.1016/j.phrs.2013.11.002)
135. Royston SE, Yasui N, Kondilis AG, Lord SV, Katzenellenbogen JA & Mahoney MM 2014 ESR1 and ESR2 differentially regulate daily and circadian activity rhythms in female mice. Endocrinology 155 2613-2623. (doi:10.1210/en.2014-1101)
136. Rubin MA 2014 Insights into the mechanism of organ-specific cancer metastasis. Cancer Discovery 4 1262-1264. (doi:10.1158/2159-8290.CD-14-1075)
137. RügerM, St Hilaire MA, Brainard GC, Khalsa SB, Kronauer RE, Czeisler CA & Lockley SW 2013 Human phase response curve to a single 6.5 h pulse of short-wavelength light. Journal of Physiology 591 353-363. (doi:10.1113/jphysiol.2012.239046)
138. Sabnis G & Brodie A 2010 Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention. Clinical Breast Cancer 18 E6. (doi:10.3816/CBC.2010.n.014)
139. Sánchez-Barceló EJ, Cos S, Mediavilla D, Martínez-Campa C, González A & Alonso-González C 2005 Melatonin-estrogen interactions in breast cancer. Journal of Pineal Research 38 217-222.
140. Santoro R, Mori F, Marani M, Grasso G, Cambria MA, Blandino G, Muti P & Strano S 2013 Blockage of melatonin receptors impairs p53-medited prevention of DNA damage accumulation. Carcinogenesis 34 1051-1061. (doi:10.1093/carcin/bgt025)
141. Sauer LA & Dauchy RT 1992 The effect of omega-6 and omega-3 fatty acids on 3H-thymidine incorporation in hepatoma 7288CTC perfused in situ. British Journal of Cancer 66 297-303. (doi:10.1038/bjc.1992.260)
142. Sauer LA, Dauchy RT & Blask DE 1997 Dietary linoleic acid intake controls the arterial blood plasma concentration and the rates of growth and linoleic acid uptake and metabolism in hepatoma 7288CTC in Buffalo rats. Journal of Nutrition 127 1412-1421.
143. Sauer LA, Dauchy RT, Blask DE, Armstrong BJ & Scalici S 1999 13-Hydroxyoctadecadienoic acid is the mitogenic signal for linoleic acid-dependent growth in rat hepatoma 7288CTC in vivo. Cancer Research 59 4688-4692.
144. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I & Colditz GA 2001 Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. Journal of the National Cancer Institute 93 1563-1568. (doi:10.1093/jnci/93.20.1563)
145. Schuster C 2007 Sites and mechanisms of action of melatonin in mammals: the MT1 and MT2 receptors. Journal de la Société de Biologie 201 85-96.
146. Schuster C, Williams LM, Morris A, Morgan PJ & Barrett P 2005 The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. Journal of Neuroendocrinology 17 170-178. (doi:10.1111/j.1365-2826.2005.01288.x)
147. Selever J, Gu G, LewisMT, Beyer A, HerynkMH, Covington KR, Tsimelzon A, Dontu G, Provost P, Di Pietro A et al. 2011 Dicer-mediated up regulation of BCRP confers tamoxifen resistance in human breast cancer cells. Clinical Cancer Research 17 6510-6521. (doi:10.1158/1078-0432.CCR-11-1403)
148. Sellix MT 2013 Clocks underneath: the role of peripheral clocks in the timing of female reproductive physiology. Frontiers in Endocrinology 4 91. (doi:10.3389/fendo.2013.00091)
149. Sims JT, Ganguly SS, BennettH, Friend JW, Tepe J&Plattner R 2013 Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1. PLoS ONE 8 e55509. (doi:10.1371/journal.pone.0055509)
150. Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS & Slominski AT 2012 Melatonin membrane receptors in peripheral tissues: Distribution and functions. Molecular and Cellular Endocrinology 351 152-166. (doi:10.1016/j.mce.2012.01.004)
151. Soto-Vega E, Meza I, Ramírez-RodríguezG&Benitez-KingG2004Melatonin stimulates calmodulin phosphorylation by protein kinase C. Journal of Pineal Research 37 98-106. (doi:10.1111/j.1600-079X.2004.00141.x)
152. Steffens F, Zhou XB, Sausbier U, Sailer C, Motejlek K, Ruth P, Olcese J, Korth M & Wieland T 2003 Melatonin receptor signaling in pregnant and non-pregnant rat uterine myocytes as probed by large conductance Ca2+-activated K+ channel activity. Molecular Endocinology 17 2103-2115. (doi:10.1210/me.2003-0047)
153. Stehle JH, von Gall C & Korf HW 2003 Melatonin: a clock-output, a clock-input. Journal of Neuroendocrinology 15 383-389. (doi:10.1046/j.1365-2826.2003.01001.x)
154. Stevens RG 1987 Electric power used and breast cancer: a hypothesis. American Journal of Epidemiology 125 556-561.
155. Stevens RG, Blask DE, Brainard GC, Hansen J, Lockley SW, Provencio I, ReaMS & Reinlib L 2007 Meeting report: the role of environmental lighting and circadian disruption in cancer and other diseases. Environmental Health Perspectives 115 1357-1362. (doi:10.1289/ehp.10200)
156. Stevenson TJ & Prendergast BJ 2013 Reversible DNA methylation regulates seasonal photoperiodic time measurement. PNAS 110 16651-16666. (doi:10.1073/pnas.1310643110)
157. Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Altieri A, Benbrahim-Tallaa L & Cogliano V 2007 Carcinogenicity of shift work, painting, and fire fighting. Lancet Oncology 8 1065-1066. (doi:10.1016/S1470-2045(07)70373-X)
158. Tamarkin L, CohenM, Roselle D, Reichert C, LippmanM& Chabner B 1981 Melatonin inhibition and pinealectomy enhancement of 7, 12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer Research 41 4432-4443.
159. Tamura H, Nakamura Y, Terron MP, Flores LJ, Manchester LC, Tan DX, Sugino N & Reiter RJ 2008 Melatonin and pregnancy in the human. Reproductive Toxicology 25 291-303. (doi:10.1016/j.reprotox.2008.03. 005)
160. Teplitzky SR, Kiefer TL, Cheng Q, Dwivedi PD, Moroz K, Myers L, Anderson MB, Collins A, Dai J, Yuan L et al. 2001 Chemoprevention of NMU-induced rat mammary carcinoma with the combination of melatonin and 9-cis-retinoic acid. Cancer Letters 168 155-163. (doi:10.1016/S0304-3835(01)00548-1)
161. Tomaskovic-Crook E, Thompson EW & Thiery JP 2009 Epithelial to mesenchymal transition and breast cancer. Breast Cancer Research 11 213. (doi:10.1186/bcr2416)
162. Truong T, Liquet B, Menegaux F, Plancoulaine S, Laurent-Puig P, Mulot C, Cordina-Duverger E, Sanchez M, Arveux P, Kerbrat P et al. 2014 Breast cancer risk, nightwork, and circadian clock gene polymorphisms. Endocrine-Related Cancer 2 629-638. (doi:10.1530/ERC-14-0121)
163. Vallabhaneni S, Nair BC, Cortez V, Challa R, Chakravarty D, Tekmal RR & Vadlamudi RK 2011 Significance of ER-Src axis in hormonal therapy resistance. Breast Cancer Research and Treatment 130 377-385. (doi:10.1007/s10549-010-1312-2)
164. Vander Heiden MG, Cantley LC & Thompson CB 2009 Understanding the Warburg effect: themetabolic requirements of cell proliferation. Science 324 1029-1033. (doi:10.1126/science.1160809)
165. Warburg O 1925 Uber den Stoffwechsel der Carcinomzelle. Klinische Wochenschrift 4 534-536. (doi:10.1007/BF01726151)
166. Wilson ST, Blask DE & Lemus-Wilson AM 1992 Melatonin augments the sensitivity of MCF-7 human breast cancer cells to tamoxifen in vitro. Journal of Clinical Endocrinology and Metabolism 75 669-670.
167. Witt-Enderby PA, Bennett J, Jarzynka MJ, Firestine S & Melan MA 2003 Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sciences 72 2183-2198. (doi:10.1016/S0024-3205(03)00098-5)
168. Woo MM, Tai CJ, Kang SK, Nathwani PS, Pang SF & Leung PC 2001 Direct action of melatonin in human granulosa-luteal cells. Journal of Clinical Endocrinology and Metabolism 86 4789-4797. (doi:10.1210/jcem.86.10.7912)
169. Wood PA, Yang X & HrusheskyWJ 2009 Clock genes and cancer. Integrative Cancer Therapies 8 303-308. (doi:10.1177/1534735409355292)
170. Wu J, Dauchy RT, Tirrell PC, Wu SS, Lynch DT, Jitawatanarat P, Burrington CM, Dauchy EM, Blask DE & Greene MW 2011 Light at night activates IGF-1R/PDK1 signaling and accelerates tumor growth in human breast cancer xenografts. Cancer Research 71 2622-2631. (doi:10.1158/0008-5472.CAN-10-3837)
171. Xiang S, Mao L, Duplessis T, Yuan L, Dauchy R, Dauchy E, Blask DE, Frasch T & Hill SM 2012 Oscillation of clock and clock controlled genes induced by serum shock in human breast epithelial and breast cancer cells: regulation by melatonin. Breast Cancer 6 137-150.
172. Xiang S, Dauchy RT, Hauch A, Mao L, Yuan L, Wren MA, Belancio VP, Mondal D, Frasch T, Blask DE et al. 2015 Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal. Journal of Pineal Research [in press]. (doi:10.1111/jpi.12239)
173. Yang S & Kim HM2014 ROCK inhibition activates MCF-7 cells. PLoS ONE 9 e88489. (doi:10.1371/journal.pone.0088489)
174. You P, Wood PA, Xiong Y, KobayashiM, Du-Quiton J & Hrushesky WJ 2005 Daily coordination of cancer growth and circadian clock gene expression. Breast Cancer Research and Treatment 91 47-60. (doi:10.1007/s10549-004-6603-z)
175. Yuan L, Collins AR, Dai J, Dubocovich ML & Hill SM 2002 MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Molecular and Cellular Endocrinology 192 147-156. (doi:10.1016/S0303-7207(02)00029-1)
176. Yuan J, Shi GX, Shao Y, Dai G, Wei JN, Chang DC & Li CJ 2008 Calmodulin bound to stress fibers but not microtubules involves regulation of cell morphology and motility. International Journal of Biochemistry & Cell Biology 40 284-293. (doi:10.1016/j.biocel.2007.08.004)
177. Zhang W, Ding W, Chen Y, Feng M, Ouyang Y, Yu Y & He Z 2011 Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. Acta Biochimica et Biophysica Sinica 43 647-653. (doi:10.1093/abbs/gmr050)
178. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M & Hung MC 2004 Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nature Cell Biology 6 931-940. (doi:10.1038/ncb1173)